BriaCell Announces Six Clinical Data Presentations at ASCO 2026

Rhea-AI Summary

BriaCell (Nasdaq: BCTX) announced six clinical data items at the 2026 ASCO Annual Meeting (May 29–June 2, 2026): three poster presentations and three publication-only abstracts covering survival, quality of life, biomarkers, and cell‑based immunotherapy in metastatic breast cancer.

Poster sessions occur May 30 and June 1, 2026; ASCO will publish abstracts May 21, 2026 at 5:00 PM ET. Poster copies will be posted at https://briacell.com/scientific-publications/ after presentation.

News Market Reaction – BCTX

+3.87%

+3.87% News Effect

On the day this news was published, BCTX gained 3.87%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement outlines six BriaCell clinical data presentations at ASCO 2026, including final ra...

Analysis

This announcement outlines six BriaCell clinical data presentations at ASCO 2026, including final randomized Phase 2 survival and quality-of-life outcomes and Phase 3 biomarker work in metastatic breast cancer. It follows a series of Bria‑IMT updates where five prior clinical-trial headlines averaged a -2.47% one-day move. Investors may watch for quantitative survival, quality-of-life, and biomarker readouts, while also considering disclosures about ongoing losses and financing needs in recent SEC filings.

Key Figures

ASCO 2026 dates: May 29–June 2, 2026 Bria-IMT survival timepoints: 12 and 24 months Breast poster boards: 221 and 222 +5 more

8 metrics

ASCO 2026 dates May 29–June 2, 2026 2026 ASCO Annual Meeting schedule

Bria-IMT survival timepoints 12 and 24 months Survival analysis with Bria-IMT + CPI in metastatic breast cancer

Breast poster boards 221 and 222 Metastatic breast cancer Bria-IMT + CPI poster board numbers

Immunotherapy poster board 442 Developmental Therapeutics—Immunotherapy biomarker poster board

Breast cancer session slot June 1, 2026, 1:30–4:30 PM CDT Bria-IMT + CPI metastatic breast cancer poster session

Immunotherapy session slot May 30, 2026, 1:30–4:30 PM CDT Bria-ABC Phase 3 biomarker poster session

Pre-news share price $3.88 Latest price before ASCO 2026 presentation news

52-week range $3.60–$98.20 Positioning near 52-week low ahead of ASCO update

Previous Clinical trial Reports

5 past events · Latest: Apr 20 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 20	AACR QoL/biomarkers	Positive	-9.3%	Phase 3 QoL preservation and Phase 2 biomarker data in metastatic breast cancer.
Dec 18	Nature Medicine feature	Positive	+3.2%	Phase 3 Bria-IMT trial highlighted among key 2026-shaping studies.
Dec 10	SABCS 2025 data	Positive	-7.9%	Phase 2 survival benefit and Phase 3 biomarker/safety data across three posters.
Dec 09	Phase 3 enrollment	Positive	-2.1%	Update that Phase 3 enrollment and interim OS analysis timing remain on track.
Dec 02	SABCS preview	Positive	+3.7%	Announcement of upcoming SABCS posters with positive Phase 2 survival and Phase 3 data.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Clinical trial and data presentations have often seen mixed-to-negative immediate price reactions despite generally positive clinical narratives.

Recent Company History

Over the past six months, BriaCell has repeatedly highlighted progress in its Bria‑IMT metastatic breast cancer program and related biomarkers. Prior clinical-trial news, including SABCS® 2025 data, Nature Medicine recognition, and AACR 2026 quality-of-life/biomarker results, emphasized favorable safety, survival signals, and FDA Fast Track designation. Market reactions to these 5 clinical-trial updates averaged about -2.47%, with three negative and two positive moves, underscoring inconsistent short-term trading responses to otherwise constructive clinical milestones.

Key Terms

phase 2, phase 3, biomarker, progression-free survival, +4 more

8 terms

phase 2 medical

"Final randomized Phase 2 Bria-IMT™ survival and quality of life data"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

phase 3 medical

"Biomarker analyses from the ongoing Phase 3 study evaluating predictors of response"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

biomarker medical

"Monitoring blood-based biomarkers as early predictors of progression-free survival"

A biomarker is a measurable indicator found in the body, such as in blood or tissues, that provides information about health, disease, or how the body responds to treatment. For investors, biomarkers can signal the potential success or risk of medical products or therapies, influencing the value of related companies and industry trends. They act like signals or clues that help assess the progress of medical advancements and their market impact.

progression-free survival medical

"biomarkers as early predictors of progression-free survival in a randomized Bria-ABC"

Progression-free survival is the length of time during and after a treatment that a patient's disease does not get worse, measured from the start of treatment until the disease shows measurable signs of progression or the patient dies. Investors care because longer progression-free survival in clinical trials often signals that a drug is effective, improving chances of regulatory approval, market adoption, and revenue potential—think of it as a stopwatch showing how long a therapy can keep the illness at bay.

immunotherapy medical

"cell-based second-generation immunotherapy BC1 in metastatic breast cancer."

Treatment that uses or enhances the body’s immune system to detect and fight disease, most often cancers or chronic infections; think of it as training or arming the body’s own soldiers to find and destroy targets. It matters to investors because successful immunotherapies can lead to high-value drug approvals, recurring revenue from long-term treatments, and changes in competitive dynamics, while failures or safety issues in clinical trials can materially affect company valuations.

liquid biopsy medical

"Liquid biopsy to stratify metastatic breast cancer progression risk using"

A liquid biopsy is a laboratory test that looks for tiny pieces of tumor or disease-related material — such as DNA, proteins, or cells — circulating in blood or other body fluids, allowing detection and monitoring without a surgical tissue sample. For investors, it matters because these tests can speed diagnosis, guide treatment choices, enable easier repeat testing, and create recurring revenue streams if adopted widely, affecting a medical company's growth and regulatory risk profile.

pd-l1 medical

"Monitoring PD-L1 expression in circulating cancer associated cells"

PD-L1 is a protein found on the surface of some cells that acts like a stop sign for the immune system, telling certain immune cells to back off. It matters to investors because many cancer drugs and diagnostic tests target or measure PD-L1 to unlock immune responses or predict which patients will benefit, affecting clinical success, regulatory approval, and potential sales in the oncology market.

immune checkpoint inhibitors medical

"prediction of clinical outcomes in metastatic breast cancer patients treated with immune checkpoint inhibitors."

Drugs that release the immune system’s natural “brakes,” allowing immune cells to recognize and attack cancer cells; imagine taking the safety off a guard dog so it can chase intruders. They matter to investors because they can become high-value treatments with large sales potential, but their commercial success depends on clinical trial results, regulatory approval, competition and side-effect management, which all affect a company’s valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Final randomized Phase 2 Bria-IMT™ survival and quality of life data to be presented
• Biomarker analyses from the ongoing Phase 3 study evaluating predictors of response
  

PHILADELPHIA and VANCOUVER, British Columbia, April 27, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce three clinical data poster presentations and three publication-only abstracts at the 2026 ASCO Annual Meeting, taking place May 29-June 2, 2026 at McCormick Place, Chicago, Illinois. The details of the poster presentation sessions and publish-only abstracts are listed below.

Abstract Title: Survival with Bria-IMT + CPI in advanced metastatic breast cancer at 12 and 24 months.
Session Type/Title: Poster Session - Breast Cancer—Metastatic
Poster Board: 222
Date and Time: June 1, 2026, 1:30 PM-4:30 PM CDT

Abstract Title: Quality of life and treatment tolerability of Bria-IMT + CPI in metastatic breast cancer.
Session Type/Title: Poster Session - Breast Cancer—Metastatic
Poster Board: 221
Date and Time: June 1, 2026, 1:30 PM-4:30 PM CDT   

Abstract Title: Monitoring blood-based biomarkers as early predictors of progression-free survival in a randomized Bria-ABC phase 3 trial for advanced metastatic breast cancer: An ongoing analysis.
Session Type/Title: Poster Session - Developmental Therapeutics—Immunotherapy
Poster Board: 442
Date and Time: May 30, 2026, 1:30 PM-4:30 PM CDT   

Publication-Only Abstract Title: Cell-based second-generation immunotherapy BC1 in metastatic breast cancer.

Publication-Only Abstract Title: Liquid biopsy to stratify metastatic breast cancer progression risk using multi-analyte cell subtyping prior to systemic therapy.

Publication-Only Abstract Title: Monitoring PD-L1 expression in circulating cancer associated cells for prediction of clinical outcomes in metastatic breast cancer patients treated with immune checkpoint inhibitors.

Presentation details will become available upon publication of the abstracts by ASCO on May 21, 2026 at 5:00 PM ET.

Following the presentation, copies of the posters will be made available at https://briacell.com/scientific-publications/.

About BriaCell Therapeutics Corp.

BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.

Safe Harbor

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about the presentation of three clinical data posters and three publication-only abstracts at the 2026 ASCO Annual Meeting and the contents of such posters, are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company's most recent Management’s Discussion and Analysis, under the heading "Risk Factors" in the Company's most recent Annual Information Form, and under “Risks and Uncertainties” in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com 

Investor Relations Contact:
investors@briacell.com

FAQ

When will BriaCell (BCTX) present clinical data at ASCO 2026?

BriaCell will present posters on May 30 and June 1, 2026 at ASCO. According to the company, three poster sessions occur May 30 and June 1, 2026, with poster board numbers and session times listed for metastatic breast cancer and immunotherapy topics.

What clinical topics will BriaCell (BCTX) cover in its ASCO 2026 posters?

The posters cover survival, quality of life, and blood biomarker analyses in metastatic breast cancer. According to the company, topics include 12‑ and 24‑month survival with Bria‑IMT + CPI, treatment tolerability, and early blood predictors of progression‑free survival.

Which BriaCell (BCTX) abstracts are publication‑only at ASCO 2026?

Three publication‑only abstracts focus on second‑generation cell therapy and liquid biopsy approaches. According to the company, titles include BC1 cell therapy, multi‑analyte liquid biopsy stratification, and PD‑L1 monitoring in circulating cancer‑associated cells.

When and where will ASCO publish BriaCell (BCTX) abstracts for 2026 presentations?

ASCO will publish the abstracts on May 21, 2026 at 5:00 PM ET. According to the company, presentation details become available upon ASCO publication, after which poster copies will be posted on the company's scientific publications webpage.

How can investors access BriaCell (BCTX) ASCO posters after presentations?

Poster copies will be posted online at the company's scientific publications page after each presentation. According to the company, posters presented at ASCO will be made available at https://briacell.com/scientific-publications/ following the live sessions.

What is the specific poster schedule for BriaCell (BCTX) at ASCO 2026?

Poster board 442 is on May 30, 2026; poster boards 221 and 222 are on June 1, 2026. According to the company, times for those poster sessions are 1:30 PM–4:30 PM CDT on the listed dates at McCormick Place, Chicago.